D-0141-2017 Class II Terminated
FDA drug recall D-0141-2017 was initiated by Sandoz Inc on Nov 9, 2016 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised. The recall status is terminated (terminated Oct 17, 2017). Affected quantity: 33,624 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 23, 2016
- Initiation Date
- Nov 9, 2016
- Termination Date
- Oct 17, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 33,624 vials
Product description
L-Cysteine Hydrochloride Injection, USP, 50 mg/mL, 50 mL Pharmacy Bulk Package Vials (NDC 66758-005-01), packaged in 5 x 50 mL Vials per carton(NDC 66758-005-02), Rx only, Manufactured for: Sandoz, Inc., Princeton, NJ.
Reason for recall
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.
Distribution pattern
Nationwide throughout the USA
Code information
Lot #: 2070915, 2071015, 2071415, 2071515, 2071615, 2071715, 2072115, 2072215, Exp 07/17; 2092315, 2093015, Exp 09/17; 2100115, Exp 10/17; 2120115, 2120215, Exp 12/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0141-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026